Study Evaluating Prevenar in High-Risk Children

Prospective Post-Marketing Surveillance Study of Prevenar in High-Risk Children Aged 2 to 5 Years

The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.

Inclusion Criteria:

• High-risk children ages 2 to 5 years old

Exclusion criteria:

• Prior administration of Prevenar
• Prior and/or concurrent administration of 23 vPs vaccine